PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
This is a Pharmacokinetic and Pharmacodynamic study evaluating the safety of co-administering
 Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination
 treatment for LF. Individuals will be randomised to receive Azithromycin alone, IDA or
 combination therapy. Clinical and biochemical monitoring for safety will be undertaken. Drug
 levels will be measured in each of the three arms to assess whether combination therapy
 significantly alters drug levels.
Inclusion Criteria:

 -  Adult aged 18-65

 -  Able to give informed consent

 Exclusion Criteria:

 -  Known chronic illness

 -  Hb <7 at baseline

 -  Liver function or Creatinine * 1.5 Upper Limit of Normal

 -  Urinary tract infection at baseline

 -  Pregnancy (female participants only)

 -  Routine medications which interact with study drugs

 -  Lactose/Gluten intolerance

 -  Permanent disability impeding study participation